A phase III double-blind, placebo-controlled trial of long term therapy of herpes simplex encephalitis (HSE): an evaluation of valacyclovir [valaciclovir] (CASG-204).

Trial Profile

A phase III double-blind, placebo-controlled trial of long term therapy of herpes simplex encephalitis (HSE): an evaluation of valacyclovir [valaciclovir] (CASG-204).

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex encephalitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual patient number (91) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top